Why the study?
Patients with type 2 diabetes and atrial fibrillation have higher risks of stroke and adverse outcomes, and direct oral anticoagulants have emerged as preferred agents for long-term stroke prevention in these individuals.
Do direct oral anticoagulants prevent stroke in patients with type 2 diabetes and atrial fibrillation?
Do direct oral anticoagulants prevent stroke in patients with type 2 diabetes and atrial fibrillation?
Direct oral anticoagulants are highlighted as a preferred choice for long-term stroke prevention in patients with atrial fibrillation and type 2 diabetes due to their predictable anticoagulation and favorable pharmacology.
DOACs preferred for T2D-AF stroke prevention; review leaves open optimal agent selection and long-term outcomes.
Type 2 diabetes (T2D) is an independent risk factor of stroke and systemic embolism in patients with atrial fibrillation (AF), and T2D patients with AF-associated stroke seem to have worse clinical outcome and higher risk of unfavorable clinical course compared to individuals without this metabolic disorder. Long-term anticoagulation is indicated in majority of T2D patients with AF to prevent adverse AF-associated embolic events. Direct oral anticoagulants (DOACs), direct oral thrombin inhibitor dabigatran, and direct oral factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, have emerged as a preferred choice for long-term prevention of stroke in AF patients offering potent and predictable anticoagulation and a favorable pharmacology with low risk of interactions. This article reviews the current data regarding the use of DOACs in individuals with T2D and AF.
No takes yet. Share an insight, caveat, or question.
Prídavková et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: